Importantly, the finding that genetic variation in the IL28B gene is associated with responsiveness to chronic hepatitis C strongly implies that there are biological connections between IL28B and hepatitis C. However, like many low molecular weight polypeptide drugs, the native IL28B is rapidly cleared through the kidney and has a short plasma half-life, reducing its efficacy and bioavailability. The gene discussed is IFNL3; the disease is chronic hepatitis C virus infection.